Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accumulated Depreciation (2022 - 2026)

Kura Oncology has reported Accumulated Depreciation over the past 5 years, most recently at $3.2 million for Q1 2026.

  • Quarterly Accumulated Depreciation fell 7.82% to $3.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Mar 2026, down 7.82% year-over-year, with the annual reading at $2.9 million for FY2025, 11.45% down from the prior year.
  • Accumulated Depreciation was $3.2 million for Q1 2026 at Kura Oncology, up from $2.9 million in the prior quarter.
  • Over five years, Accumulated Depreciation peaked at $3.9 million in Q3 2025 and troughed at $1.6 million in Q4 2022.
  • The 5-year median for Accumulated Depreciation is $2.9 million (2024), against an average of $2.8 million.
  • Year-over-year, Accumulated Depreciation surged 52.96% in 2023 and then decreased 11.45% in 2025.
  • A 5-year view of Accumulated Depreciation shows it stood at $1.6 million in 2022, then surged by 52.96% to $2.5 million in 2023, then surged by 33.56% to $3.3 million in 2024, then fell by 11.45% to $2.9 million in 2025, then grew by 11.76% to $3.2 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Accumulated Depreciation are $3.2 million (Q1 2026), $2.9 million (Q4 2025), and $3.9 million (Q3 2025).